Neuren Pharmaceuticals Ltd (ASX: NEU) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Neuren Pharmaceuticals Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $472.37 million
P/E Ratio N/A
Dividend Yield N/A
Shares Outstanding 128.97 million
Earnings per share -0.066
Dividend per share N/A
Year To Date Return 0.80%
Earnings Yield N/A
Franking N/A
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

Neuren Pharmaceuticals Ltd (ASX: NEU)
Latest News

pills spilling from bottle
Share Market News

Why this ASX pharmaceutical share is on the move today

The Neuren Pharmaceuticals Ltd (ASX: NEU) share price is ont the move today following news of an FDA grant.

Read more »

Share Fallers

Why Neuren Pharma, OFX, Rural Funds, & Syrah shares dropped lower

The OFX Group Ltd (ASX:OFX) share price and the Rural Funds Group (ASX:RFF) share price are two of four ending…

Read more »

share price higher
Share Gainers

Why Afterpay, IDP Education, Neuren, & NRW Holdings stormed higher today

The Afterpay Touch Group Ltd (ASX:APT) share price and the Neuren Pharmaceuticals Ltd (ASX:NEU) share price are two of four…

Read more »

production of drugs in the lab
Share Gainers

Why the Neuren Pharmaceuticals share price rocketed 50% higher today

The Neuren Pharmaceuticals Ltd (ASX:NEU) share price rocketed 50% higher this morning following the release of two positive announcements...

Read more »

Acquisition
Share Market News

Insiders have been buying these ASX shares

Insiders have been buying the shares of Praemium Ltd (ASX:PPS) and two others this week…

Read more »

Rising ASX share price represented by investors jumping high in the air
Share Gainers

Why these 4 ASX shares jumped higher today

The Tabcorp Holdings Limited (ASX:TAH) share price is one of four jumping higher today. Here’s why…

Read more »

stock chart heads down
Share Fallers

Why these 4 ASX shares have dropped lower today

The Eclipx Group Ltd (ASX:ECX) share price is one of four dropping lower on Tuesday. Here’s why…

Read more »

Share Fallers

Why Neuren Pharmaceuticals Ltd (ASX:NEU) shares have been smashed today

Neuren Pharmaceuticals Ltd (ASX: NEU) share price has been smashed today. Here's what you need to know...

Read more »

NEU ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
YesNo

About Neuren Pharmaceuticals Ltd

Neuren Pharmaceuticals Ltd is a biopharmaceutical company, which engages in the development of new therapies for brain injury, neurodevelopment, and neurodegenerative disorders. Its drugs target symptoms resulting from acute traumatic brain injury, as well as symptoms of chronic conditions, such as Rett syndrome and Fragile X syndrome.

NEU Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
06 Jul 2022 $3.75 $-0.05 -1.32% 206,605 $3.77 $3.96 $3.75
05 Jul 2022 $3.80 $0.08 2.15% 57,493 $3.84 $3.86 $3.76
04 Jul 2022 $3.72 $-0.02 -0.53% 120,457 $3.75 $3.90 $3.72
01 Jul 2022 $3.74 $-0.06 -1.58% 73,174 $3.73 $3.86 $3.73
30 Jun 2022 $3.80 $0.09 2.43% 83,274 $3.70 $3.80 $3.69
29 Jun 2022 $3.71 $-0.04 -1.07% 49,764 $3.73 $3.79 $3.66
28 Jun 2022 $3.75 $-0.03 -0.79% 29,503 $3.80 $3.80 $3.73
27 Jun 2022 $3.78 $0.08 2.16% 54,208 $3.70 $3.83 $3.66
24 Jun 2022 $3.70 $0.09 2.49% 91,157 $3.72 $3.77 $3.63
23 Jun 2022 $3.61 $0.05 1.40% 92,293 $3.62 $3.70 $3.59
22 Jun 2022 $3.56 $0.08 2.30% 125,206 $3.50 $3.66 $3.47
21 Jun 2022 $3.48 $0.01 0.29% 275,613 $3.50 $3.59 $3.44
20 Jun 2022 $3.47 $-0.04 -1.14% 103,691 $3.43 $3.52 $3.43
17 Jun 2022 $3.51 $-0.01 -0.28% 96,726 $3.50 $3.51 $3.37
16 Jun 2022 $3.52 $0.02 0.57% 77,037 $3.51 $3.56 $3.47
15 Jun 2022 $3.50 $-0.02 -0.57% 169,819 $3.57 $3.57 $3.33
14 Jun 2022 $3.52 $-0.14 -3.83% 291,345 $3.60 $3.65 $3.36
10 Jun 2022 $3.66 $-0.10 -2.66% 146,590 $3.69 $3.78 $3.63
09 Jun 2022 $3.76 $-0.04 -1.05% 123,084 $3.87 $3.87 $3.69
08 Jun 2022 $3.80 $-0.06 -1.55% 190,273 $3.90 $3.95 $3.75
07 Jun 2022 $3.86 $0.05 1.31% 95,785 $3.80 $3.86 $3.70

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
18 Oct 2021 Dianne Angus Buy 30 $59,316
On-market trade.
08 Oct 2021 Jonathan (Jon) Pilcher Buy 7 $15,000
Participation in share purchase plan.
08 Oct 2021 Jenny Harry Buy 9 $20,000
Participation in share purchase plan.
08 Oct 2021 Patrick Davies Buy 14 $30,000
Participation in share purchase plan.

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Dr Trevor D Scott Non-Executive Director Mar 2002
Dr Scott is the founder of T.D. Scott and Co., an accountancy and consulting firm, which he formed in 1988. He is an experienced advisor to companies across a variety of industries. Trevor serves on numerous corporate boards and is chairman of several.
Ms Dianne Margaret Angus Non-Executive Director Jul 2018
Ms Angus has worked as a senior executive and non-executive director within the biotechnology, biopharmaceutical and agritech industries for over twenty-five years. She has created numerous global industry partnerships which include Prana Biotechnology, Gerolymatos International, Florigene, Suntory & Monsanto to yield novel and competitive medical, pharmaceutical and agricultural products. Dianne has successfully forged partnerships with key medical opinion leaders to create innovative clinical research programs and driven the development path for novel neurological pre-clinical agents to late-stage clinical assets before the FDA and European regulators. With over fifteen years experience in an ASX and NASDAQ listed company, she has expertise in business development, capital raising, investor relations, regulatory affairs and intellectual property, together with corporate governance and compliance capabilities.
Mr Jonathan (Jon) Charles Pilcher Chief Executive OfficerManaging Director Aug 2013
Mr Pilcher has played a central role in all aspects of Neuren's R&D, commercial and corporate activities. Before joining Neuren he was a member of the leadership team at Acrux (ASX: ACR) throughout a period that included Acrux's IPO and listing on the ASX, the development and FDA approval of three novel pharmaceutical products and a transforming licensing deal with Eli Lilly in 2010. He formerly spent seven years in a series of senior financial positions in the R&D and corporate functions of international pharmaceutical groups Medeva and Celltech, which are now part of UCB. Jon is a Chartered Accountant and holds a degree in Biotechnology from the University of Reading in the UK.
Dr Jenny Lee Harry Non-Executive Director Jul 2018
Dr Harry has 20 years experience in executive management of companies in the biotechnology and biopharmaceutical sectors. Jenny is an accomplished CEO and Managing Director with experience in growing companies from start-up to commercialisation.
Mr Patrick Davies Non-Executive DirectorNon-Executive Chairman Jul 2018
Mr Davies has held executive management roles in the Australian and New Zealand healthcare industry for over twenty five years having performed successfully in senior roles across many industry sectors including pharmacy, primary care, pharmaceutical and consumer products. During his ten year period as Chief Executive Officer of EBOS Group Limited and previously Symbion), the enterprise value of the group achieved compound annual growth in enterprise value of +20% (from circa $450M to in excess of $3.1B). He is a director on other corporate boards and provides strategic advice to a range of healthcare businesses and investors.
Ms Lauren Frazer Chief Financial OfficerCompany Secretary Aug 2020
-
Lauren Frazer Chief Financial Officer & Company Secretary
-
Lauren Frazer Chief Financial OfficerCompany Secretary
-
Larry Glass Chief Science Officer
-
Virginie Durez Senior Director Product Development & Project Management
-
James Shaw Vice President Clinical & Regulatory Operations
-
Nancy Jones Vice President Clinical Development
-
Gerry Zhao Vice President Corporate Development
-
Clive Blower Vice President Product Development
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
HSBC Custody Nominees (Australia) Limited Gsco Eca 14,473,054 11.49%
National Nominees Limited 12,475,013 9.90%
Citicorp Nominees Pty Limited 9,417,997 7.48%
Cameron Richard Pty Ltd 5,432,260 4.31%
Stuart Andrew Pty Ltd 2,667,146 2.12%
Linwierik Super Pty Ltd 2,639,643 2.10%
Hsbc Custody Nominees (Australia) Limited 2,592,919 2.06%
Essex Castle Limited 2,367,144 1.88%
Smithley Super Pty Ltd 2,148,000 1.71%
Hobson Wealth Custodians Ltd 1,595,901 1.27%
Mxb Investments Llc 1,330,000 1.06%
First Colbyco Pty Ltd 1,032,854 0.82%
Sharesies Nominee Limited 1,011,875 0.80%
Dr Trevor Scott 1,000,000 0.79%
Dr Robin Lance Congreve 991,637 0.79%
J P Morgan Nominees Australia Pty Limited 926,986 0.74%
BNP Paribas Noms Pty Ltd 913,170 0.72%
Hsbc Custody Nominees (Australia) Limited A/C 2 821,336 0.65%
10 Bolivianos Pty Ltd 754,116 0.60%
BNP Paribas Nominees Pty Ltd Six Sis Ltd 631,525 0.50%

Profile

since

Note